Urothelial carcinoma (bladder + upper tract) · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | None |
| ID | IND-IATROGENIC-CYCLOPHOSPHAMIDE-LATE-PREVENTION-SURVEILLANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-UROTHELIAL |
| Sources | SRC-COG SRC-NCCN-AML-2025 SRC-NCCN-BCELL-2025 SRC-NCCN-BLADDER-2025 |
Notes
STUB — cancer-survivor late-effects pilot (cyclophosphamide). Two surveillance domains: bladder cancer (primary anchor DIS-UROTHELIAL — acrolein-driven urothelial damage), t-AML/MDS (CBC q3-6mo for first 5y, co-managed with RF-IATROGENIC-ALKYLATOR-TAML-PREVENTION). Two-Clinical-Co-Lead signoff queued.
Used By
No reverse references found in the YAML corpus.